Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial
Pieter Sonneveld, Meletios A Dimopoulos, Meral Beksaç, Bronno van der Holt, Francesca Gay, Heinz Ludwig, Sonja Zweegman, Vladimír Maisnar, Maria Teresa Petrucci, Paolo Corradini, Fabrizio Patriarca, Angelo Belotti, Micol Quaresima, Mariella Grasso, Massimo Offidani, Laura París, Anna Marina Liberati, Markus Hansson, Heleen Visser-Wisselaar, Giulia Fumero, Renato Zambello, Paula F. Ypma, Anna Pascarella, Niels Frost Andersen, Alexandra Croockewit, Mario Boccadoro, Michèle Cavo (2024). Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial. , 144(Supplement 1), DOI: https://doi.org/10.1182/blood-2024-197908.
Article37 days agoLong-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)
Fredrik Schjesvold, Meletios A Dimopoulos, Sosana Delimpasi, Paweł Robak, Daniel Coriu, Wojciech Legieć, Luděk Pour, Ivan Špıčka, Tamás Masszi, Vadim Doronin, Jiří Minařík, Galina Salogub, Yulia Alexeeva, Antonio Lazzaro, Vladimír Maisnar, Gábor Mikala, Stefan Norin, Marcus Thuresson, A. Bergan, Jakob Obermüller, Roman Hájek, María‐Victoria Mateos, Paul G. Richardson, Pieter Sonneveld (2023). Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM). , 142(Supplement 1), DOI: https://doi.org/10.1182/blood-2023-177945.
Article37 days agoLong-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)
Fredrik Schjesvold, Meletios A Dimopoulos, Sosana Delimpasi, Paweł Robak, Daniel Coriu, Wojciech Legieć, Luděk Pour, Ivan Špıčka, Tamás Masszi, Vadim Doronin, Jiří Minařík, Galina Salogub, Yulia Alexeeva, Antonio Lazzaro, Vladimír Maisnar, Gábor Mikala, Stefan Norin, Marcus Thuresson, A. Bergan, Jakob Obermüller, Roman Hájek, María‐Victoria Mateos, Paul G. Richardson, Pieter Sonneveld (2023). Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM). , 142(Supplement 1), DOI: https://doi.org/10.1182/blood-2023-177945.
Article37 days agoLong-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)
Fredrik Schjesvold, Meletios A Dimopoulos, Sosana Delimpasi, Paweł Robak, Daniel Coriu, Wojciech Legieć, Luděk Pour, Ivan Špıčka, Tamás Masszi, Vadim Doronin, Jiří Minařík, Galina Salogub, Yulia Alexeeva, Antonio Lazzaro, Vladimír Maisnar, Gábor Mikala, Stefan Norin, Marcus Thuresson, A. Bergan, Jakob Obermüller, Roman Hájek, María‐Victoria Mateos, Paul G. Richardson, Pieter Sonneveld (2023). Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM). , 142(Supplement 1), DOI: https://doi.org/10.1182/blood-2023-177945.
Article37 days agoOAB-050: OCEAN (OP-103): a Phase 3, randomized, global, head-to-head comparison study of Melflufen and Dexamethasone (Dex) versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)
Fredrik Schjesvold, Meletios A Dimopoulos, Sosana Delimpasi, Pawef Robak, Daniel Coriu, Wojciech Legieć, Luděk Pour, Ivan Špıčka, Tamás Masszi, Vadim Doronin, Jiří Minařík, Galina Salogub, Yulia Alexeeva, Antonio Lazzaro, Vladimír Maisnar, Gábor Mikala, Victoria Moody, Marcus Thuresson, Catriona Byrne, Johan Harmenberg, Roman Hájek, María‐Victoria Mateos, Paul G. Richardson, Pieter Sonneveld (2021). OAB-050: OCEAN (OP-103): a Phase 3, randomized, global, head-to-head comparison study of Melflufen and Dexamethasone (Dex) versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM). , 21, DOI: https://doi.org/10.1016/s2152-2650(21)02124-8.
Article37 days ago